Compare · BDX vs NPCE
BDX vs NPCE
Side-by-side comparison of Becton Dickinson and Company (BDX) and Neuropace Inc. (NPCE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and NPCE operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $72.89B, about 361.2x NPCE ($201.8M).
- BDX has been more active in the news (9 items in the past 4 weeks vs 3 for NPCE).
- BDX has more recent analyst coverage (25 ratings vs 15 for NPCE).
- Company
- Becton Dickinson and Company
- Neuropace Inc.
- Price
- -
- -
- Market cap
- $72.89B
- $201.8M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 9
- 3
- Recent ratings
- 25
- 15
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Neuropace Inc.
NeuroPace, Inc. operates as a medical device company in the United States. The company develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. Its RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Latest BDX
- BD Earns Industry Top Honors for Transparency, Resiliency and Partnership
- Goldman resumed coverage on Becton Dickinson with a new price target
- Becton Dickinson and Company filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- BD to Announce Financial Results for its Second Quarter of Fiscal 2026
- Rick Byrd to Retire from BD
- For Women Managing Nighttime Incontinence, Better Sleep and Comfort Start with BD® PureWick® Urine Collection System
- BD Delivers Next‑Generation TIPS Innovation to Advance Portal Hypertension Care Across the European Union
- When Every Beat Matters, BD Helps Clinicians Eliminate Blind Spots with Continuous, Noninvasive Blood Pressure Insight
- SEC Form 4 filed by Neal Shana Carol
- Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest NPCE
- SEC Form DEFA14A filed by Neuropace Inc.
- SEC Form DEF 14A filed by Neuropace Inc.
- NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference
- SEC Form 4 filed by Morrell Martha
- SEC Form 4 filed by Geiger Uri
- SEC Form 4 filed by Lacob Joseph
- SEC Form 4 filed by Kumar Rakhi
- SEC Form 4 filed by Fischer Frank M
- NeuroPace to Present at the Leerink Global Healthcare Conference
- CHIEF MEDICAL OFFICER Morrell Martha sold $399,250 worth of shares (25,000 units at $15.97) and covered exercise/tax liability with 1,340 shares, decreasing direct ownership by 35% to 48,624 units (SEC Form 4)